News
The company plans to divest a drug it has made for 40 years, citing increasing production costs and falling prices.
FEATURED STORIES
Corsera Healthâs Chief Operating Officer Rena Denoncourt and CFO Meredith Kaya speak with BioSpace about the biotechâs mission and vision for the next generation of cardiovascular care.
Billions of dollarsâ worth of cancer drugs are discarded each year. Manufacturers must refund Medicare for some of this waste. A data-driven approach offers a practical path to greater efficiency.
Sales of Merckâs longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Following the FDAâs refusal to review Modernaâs investigational mRNA flu vaccine last week, Commissioner Marty Makary faced questions from the U.S. president about the agencyâs handling of vaccines. Itâs a clear signal that the tension long brewing at the drug regulator has now gone all the way to the top.
THE LATEST
The FDA outright refuses to review Modernaâs mRNA-based flu vaccine as CBER director Vinay Prasadâs conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have had a hand in; Compass Pathways posts new late-stage data on its psilocybin-based depression drug; CDC is once again leaderless.
With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassmanâs Michael Pietrack discusses how pressure builds and what can ease it.
PitchBookâs 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with later-stage programs ready to roll into the clinic.
Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressedâand thereâs more to come in 2026.
Regulatory uncertainty is no longer background noise. It is a material investment risk that reshapes how capital is deployed and pipelines are prioritized.
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
Disc Medicineâs leadership tried to express optimism that its rare disease therapy bitopertin can be approved based on a Phase 3 trial set to begin shortly. However, analysts are worried that the protocol was developed with former FDA leaders.
Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical Officer Guy Goodwin. By providing 26 weeksâ worth of such data instead of the requested 12, the company is delivering âin spades,â he said.
Competing with giants like Takeda and Moderna, the plucky biotech believes it has unlocked a future with an easy, yearly oral vaccine.
Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to determine a regulatory path for Axpaxli.